Stryker Corporation

ticker: SYK step: 01 generated: 2026-05-12 source: quick-research

Stryker Corporation (SYK) — Business Overview

Business Description

Stryker is one of the world's leading medical technology companies, with a market-leading position in robotic-assisted orthopedic surgery (Mako platform, 3,000+ installations + 2M+ procedures) plus broad MedSurg + Neurotechnology + Orthopaedics portfolios. CEO Kevin Lobo (since 2012). The $4.9B Inari Medical acquisition (2025) added vascular/VTE intervention as a new growth pillar. Mako spine + Mako shoulder launches in 2026 expand the robotic surgery franchise into adjacent specialties. In Q1 2026, Stryker reorganized: combining Mako + power tools + Ortho instruments into a new "Ortho Tech" business.

Revenue Model

• MedSurg and Neurotechnology (~58% of revenue): Instruments (power tools), Endoscopy, Medical (patient handling, EMS), Neurotechnology (neurosurgical, neurovascular, CMF)
• Orthopaedics (~42%): Joint replacement (knees, hips, shoulders), Trauma & Extremities, Spine, plus Mako enabling technology
• Recurring revenue from disposables + maintenance contracts + procedural consumables

Products & Services

Mako Robotic-Assisted Surgery

• Mako SmartRobotics: Multi-specialty robotic-arm assisted platform
• Mako 4: Latest generation (released 2024)
• Mako RPS (Robotic Power System): New handheld robotic system — limited market release 2026
• Mako Total Knee, Partial Knee, Total Hip, Revision Hip
• Mako Spine (full launch 2026)
• Mako Shoulder (full launch 2026)
• 3,000+ installations globally; 2M+ procedures cumulative

Orthopaedics

• Joint Replacement: Triathlon (knee), Tritanium (hip), MyKnee custom
• Trauma & Extremities: Pangea trauma system (global rollout), foot/ankle implants
• Spine: Tritanium spine system, navigation
• Ortho Tech (reorganized 2026): Combines Mako + power tools + Ortho instruments

MedSurg / Neurotechnology

• Instruments: Power tools (drills, saws, surgical drills) — largest installed base
• Endoscopy: 4K imaging, surgical visualization
• Medical: Stretchers, ICU beds, ambulance equipment, hospital communication, virtual care
• Neurosurgical: Neuroendoscopy, cranial implants
• Neurovascular: Trevo stent retrievers, aspiration systems for stroke
• Inari Medical (acquired 2025 for $4.9B): ClotTriever + FlowTriever for VTE
• Craniomaxillofacial (CMF): Cranial implants, plates, screws

Customer Base & Go-to-Market

• Hospitals + ambulatory surgery centers: Primary buyers
• Orthopaedic surgeons: Mako-trained network growing rapidly
• Neurosurgeons + interventional radiologists: Neurotechnology customers
• EMS providers: Medical products
• Geographic mix: ~75% US, ~25% International (growing internationally)
• Channel: Direct sales force + distributors internationally

Competitive Position

Stryker is #1 globally in orthopaedic robotic-assisted surgery (Mako vs Smith+Nephew CORI, J&J Velys, Zimmer ROSA). Moats: (1) Mako installed base of 3,000+ creates surgeon training network with switching costs, (2) deep relationships with US ortho practices, (3) Pangea trauma system gaining global share, (4) Inari VTE platform entering high-growth market. Competitors: J&J MedTech (orthopaedics + endoscopy), Medtronic (broad), Zimmer Biomet (orthopaedics), Smith+Nephew, Boston Scientific (in VTE).

Key Facts

• Founded: 1941 (Dr. Homer Stryker)
• Headquarters: Portage, MI
• Employees: ~52,000
• Exchange: NYSE
• Sector / Industry: Health Care / Medical Devices
• Market Cap: ~$155B (May 2026)
• CEO: Kevin Lobo (since 2012)
• Dividend: $3.40 annual ($0.85 quarterly)
• 30+ consecutive years of dividend growth
• Major recent M&A: Inari Medical $4.9B (2025)

ticker: SYK step: 04 generated: 2026-05-12 source: quick-research

Stryker Corporation (SYK) — Financial Snapshot

Income Statement Summary

Segment Performance (FY2025)

Q1 2026 Highlights

Mako Installations + Procedures

2026 Guidance

Cash Flow & Balance Sheet (FY2025)

Inari Medical Acquisition (2025)

Key Ratios (approximate, May 2026)

• P/E (forward): ~28x | EV/EBITDA: ~20x | Dividend Yield: ~0.95%
• ROIC: ~15%
• FCF Margin: ~14%

Growth Profile

FY25 revenue +11% to $25.1B; adj EPS +12% to $13.63. Q1 2026 sales only +2.6% due to $310M cyberattack revenue shortfall (3-week shutdown). Reaffirmed 2026 guidance at 8-9.5% organic + $14.90-15.10 EPS. Mako installations record; Mako Spine + Shoulder full launches in 2026. Inari VTE adding $100M+ synergies in 2026.

Forward Estimates

• FY2026E Revenue: ~$27B (+8-9%, includes tariff drag offset)
• FY2026E Adj EPS: $14.90-15.10 (mgmt)
• FY2027E EPS: ~$17 (+13%)
• Long-term EPS growth target: 10-15%
• Mako Spine + Shoulder peak sales potential: $500M+ annually

Capital Return

• Dividend $3.40 annual (~$1.3B paid)
• 30+ consecutive years of dividend growth
• Buybacks: ~$1B annual (moderated for Inari deleveraging)
• Total return: ~1% dividend + buybacks + 10-15% EPS growth

ticker: SYK step: 12 generated: 2026-05-12 source: quick-research

Stryker Corporation (SYK) — Investment Catalysts & Risks

Bull Case Drivers

1. Mako Spine + Shoulder full launch 2026 — $500M+ peak potential — Mako's 2026 expansion into spine and shoulder procedures could unlock $500M+ in annual revenue. Mako now has 3,000+ installations and 2M+ procedures cumulative. Adding two new specialties leverages the same trained-surgeon network + capital sales motion. The Mako moat compounds: each additional specialty makes the platform more valuable to a hospital.

2. Mako RPS handheld + Q1 2026 record installations — Mako RPS (Robotic Power System) is a new handheld robotic system that combines Mako's robotics + power tools. Limited market release 2026. Q1 2026 marked best-ever Mako installations globally + US. The "Ortho Tech" reorganization (Mako + power tools + Ortho instruments) simplifies the customer offering and accelerates innovation cadence.

3. Inari Medical acquisition — VTE platform entry — $4.9B Inari acquisition (2025) adds ClotTriever + FlowTriever for VTE (venous thromboembolism). VTE is a high-growth med tech market with strong clinical momentum. $100M+ synergies expected in 2026. Diversifies Stryker beyond orthopaedics into vascular intervention.

4. 30-year dividend growth track record + organic 8-9.5% guide — Stryker has grown its dividend for 30+ consecutive years. 2026 organic sales guide of 8-9.5% is mid-to-high single digit growth even with $200M tariff headwind absorbed. Adj EPS guide $14.90-15.10 = double-digit EPS growth. Combined with 1% dividend + buybacks = ~14-16% total return potential.

Bear Case Risks

1. Q1 2026 cyberattack — $310M revenue shortfall — A March 2026 cyber incident shut down manufacturing for 3 weeks, costing $310M in lost revenue. Gross margin compressed 190bps from lost manufacturing absorption + tariffs. Bears worry that not all of this revenue comes back. Cyber risk is a recurring theme for med tech companies (Boeing, Solar Winds, MOVEit) and SYK's exposure is now visible.

2. 28x forward P/E — premium med-tech multiple — Stryker trades at ~28x forward EPS vs. healthcare equipment sector ~22x. Premium reflects Mako quality, but Q1 2026 stock fell 6% on earnings — narrative is moving from "best-in-class compounder" to "execution check." Any further surgery slowdown or M&A integration stumble compresses multiple.

3. Tariff headwind + margin pressure — $200M revenue headwind in 2026 from tariffs. Adj gross margin compressed 190bps in Q1 26 from tariffs + cyber. If tariffs escalate or persist into 2027, margin recovery thesis slips. Bear case: tariffs become a permanent ~150bps drag.

4. Inari integration risk — $4.9B Inari deal increased interest expense significantly. VTE intervention market has competitive intensity (Boston Scientific Janus, Penumbra). If Inari integration disappoints or growth slows, the $100M+ 2026 synergy doesn't materialize and bear case develops.

Upcoming Events

• Q2 2026 earnings (July 2026) — Mako Spine + Shoulder launch tracking; cyber recovery; tariff impact
• Q3 2026 earnings (October 2026) — Mid-year guide reset
• AAOS 2027 (March 2027) — Annual ortho surgeon conference; Mako platform innovation showcases
• Inari synergy realization — Multi-quarter integration milestones
• Tariff developments — Ongoing tariff escalation/de-escalation impacts

Analyst Sentiment

Sell-side consensus is Buy with average price targets in the $440-470 range vs. recent ~$400 trading levels (~10-18% upside). Bulls cite Mako Spine + Shoulder catalysts, Inari VTE platform, 30-year dividend track record. Bears focus on 28x P/E, cyber + tariff impacts. Stock is one of the most consistent compounders in med tech but faces near-term turbulence.

Research Date

Generated: 2026-05-12